Parker Institute for Cancer Immunotherapy, Resilience partner to develop cell and gene therapies

Engineered HSV can trigger genetic chain reaction, rearrange HSV genes during co-infection

In preclinical work recently published in Nature Communications, Fred Hutchinson Cancer Center scientists used a genetic “chain reaction” to transform herpes simplex virus DNA during an HSV infection.

November 15, 2024

Vol.50 No.43

Drugs & Targets

Humana and Evolent expand partnership to enhance oncology care

Humana Inc. and Evolent Health Inc. announced an expansion of their strategic medical oncology partnership to modernize and streamline prior authorization processes to include radiation and surgical oncology services.

November 15, 2024

Vol.50 No.43

In Brief

MD Anderson and industry partners to conduct T cell studies on the International Space Station

The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station to study the effects of prolonged microgravity on cell differentiation, activation, memory, and exhaustion.

August 02, 2024

Vol.50 No.31

In Brief

City of Hope Atlanta opens Blood and Marrow Transplantation and Cell Therapy Program

City of Hope has opened a Blood and Marrow Transplantation and Cell Therapy Program at City of Hope Cancer Center Atlanta.

March 29, 2024

Vol.50 No.13

In Brief

A. Samer Al-Homsi named system chief of blood and marrow transplant and cellular therapy at Northwell

A. Samer Al-Homsi, a leader in hematology, was appointed as system chief of blood and marrow transplant and cellular therapy at the Northwell Health Cancer Institute.

March 29, 2024

Vol.50 No.13

Clinical

First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.

February 23, 2024

Vol.50 No.08

By Matthew Bin Han Ong

Parker Institute for Cancer Immunotherapy, Resilience partner to develop cell and gene therapies

YOU MAY BE INTERESTED IN

Engineered HSV can trigger genetic chain reaction, rearrange HSV genes during co-infection

Humana and Evolent expand partnership to enhance oncology care

MD Anderson and industry partners to conduct T cell studies on the International Space Station

City of Hope Atlanta opens Blood and Marrow Transplantation and Cell Therapy Program

A. Samer Al-Homsi named system chief of blood and marrow transplant and cellular therapy at Northwell

First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

Renew today!

Subscriber content

Login